Results 131 to 140 of about 7,362 (230)

Effect of esomeprazole on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera oestrogen receptor degrader, in healthy participants

British Journal of Clinical Pharmacology, Volume 92, Issue 10, Page 3477-3484, October 2026.
Aims The aim of this study is to evaluate the effects of multiple doses of esomeprazole, a strong proton pump inhibitor and acid‐reducing agent, on the pharmacokinetics and safety of vepdegestrant, a PROteolysis TArgeting Chimera oestrogen receptor degrader.
Lana Tran, Naihan Chen, Jennifer A. Winton, Kyle T. Matschke, Smita P. Goodman, Kimberly C. Lee, Yuanyuan Zhang, Weiwei Tan   +7 more
wiley   +1 more source

Proteolysis Targeting Chimeric-Based Technology in Myeloma and Lymphoma. [PDF]

Mol Cancer Ther
Tigu AB, Ivancuta A, Tomuleasa C, Nistor M, Kegyes D, Cenariu D, Munteanu R, Buzoianu AD, Einsele H, Federico M, Kobold S, Gulei D, Ciechanover A.   +12 more
europepmc   +1 more source

Protein‐Ratio Rheostats: Integrating Stoichiometry, Abundance, and Binding Affinity in Cellular Function

BioEssays, Volume 48, Issue 10, October 2026.
Relative protein composition can act as a rheostat by altering molecular assembly within defined abundance and binding regimes. MicroRNAs, translation, and selective degradation can reshape protein composition, influencing signaling, apoptosis, development, and disease.
Subbaya Subramanian, Reena V. Kartha
wiley   +1 more source

Nano-Proteolysis Targeting Chimeras (Nano-PROTACs) in Cancer Therapy

International Journal of Nanomedicine
Yue Song,1,* Qing-Qing Dong,2,* Yi-Ke Ni,3 Xiao-Ling Xu,3 Chao-Xiang Chen,3 Wei Chen2 1Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310003, People’s Republic of China; 2ICU ...
Song Y, Dong QQ, Ni YK, Xu XL, Chen CX, Chen W   +5 more
doaj  

Proteolysis Targeting Chimera (PROTAC) Linkerology Enhances the CDK-Degradation Selectivity Profile of a Multi-CDK Inhibitor: Discovery of Potent, Anti-Leukemic CDK9 Degraders. [PDF]

ACS Pharmacol Transl Sci
Chan AM, Eberly C, Goodis CC, Nordquist EB, Weldemariam M, Carter-Cooper BA, Pogash S, Lapidus R, Kane MA, MacKerell AD, Civin CI, Fletcher S.   +11 more
europepmc   +1 more source

CCNE1: A Cell Cycle Regulator That Influences Tumor Progression

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACTCyclin E1 (CCNE1), a pivotal member of the cyclin family, governs the G1/S phase transition of the cell cycle by binding to and activating cyclin‐dependent kinase 2 (CDK2), thereby initiating DNA replication and driving S‐phase entry. In a broad spectrum of human malignancies—including breast, ovarian, gastric, and non‐small cell lung cancers ...
Liang Yan, Siyi Liu, Yanling Li, Qian He, Chen Long, Ning Tang, Yanhong Zhou   +6 more
wiley   +1 more source

Exosome-Mediated Delivery of PROTACs for Targeted Protein Degradation in Cancer, Neurodegenerative, Infectious, and Inflammatory Diseases. [PDF]

J Cell Mol Med
Ghosh SB, Banerjee R, Almohaimeed HM, Almars AI, ALMatrafi TA, Saleh FM, Mohammedsaleh ZM, Ealla KKR, Kumer A, Dhara B.   +9 more
europepmc   +1 more source

Imine Reductase‐Mediated Regio‐ and Stereoselective Reductive Amination of Diamines

ChemCatChem, Volume 18, Issue 19, 14 October 2026.
Imine reductases (IREDs) have been employed as biocatalysts for the regioselective modification of diamines via reductive amination. The use of racemic diamines resulted in both regio‐ and enantio‐selective reductive amination via kinetic resolution. The application of this methodology has been demonstrated on a preparative scale by the synthesis of a ...
Arnau Rué Casamajo, Yuqi Yu, Lucian Pirvu, Christian Schnepel, Simon J. Charnock, Francesco Falcioni, Martin A. Hayes, Nicholas J. Turner   +7 more
wiley   +1 more source

Discovery of PROTACs recruiting the E3 ligase CHIP. [PDF]

RSC Chem Biol
Masuda-Ozawa T, Tomoshige S, Hayakawa E, Sato S, Ohgane K, Ohtake F, Ishikawa M.   +6 more
europepmc   +1 more source

Mapping Mutations and Signaling Network Interactions to Guide Precision Therapy in Gallbladder Cancer

Cancer Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background Gallbladder cancer (GBC) is a biologically complex malignancy arising from the epithelial lining of the gallbladder, with adenocarcinoma constituting the major histological subtype. Early detection is challenging because of vague clinical manifestations and the organ's deep‐seated anatomical location, resulting in diagnosis at ...
Nisha Manav, Akanksha Kashyap, Lakshay Malhotra, Chethan Rajegowda, Chandra Prakash Prasad   +4 more
wiley   +1 more source